环硅酸锆钠治疗轻中度与重度/终末期CKD高钾血症的长期安全性和有效性:一项开放标签3期研究的比较结果
这项开放标签、单臂3期研究的事后分析比较了环硅酸锆钠(SZC)在基线eGFR<30与≥30 mL/min/1.73 m²的CKD高钾血症门诊患者中超过12个月的疗效与安全性。结果显示,无论CKD分期,SZC均可纠正高钾血症并维持血钾正常,但eGFR<30亚组维持期不良事件更常见。
要点
- SZC可有效纠正并维持CKD高钾血症患者的血钾正常,不受CKD分期影响。
- 纠正期24小时内两亚组均有82%患者达到血钾正常,72小时内eGFR<30组达100%、≥30组达95%。
- 维持期第365天eGFR<30组82%、≥30组90%维持血钾正常,eGFR<30组不良事件更常见。
核心结论
- SZC可纠正高钾血症并在CKD门诊患者中维持血钾正常,无论CKD分期。
研究设计与样本
- 开放标签、单臂3期研究(NCT02163499)的事后分析,纳入751例血清钾≥5.1 mmol/L的成人门诊患者。
主要发现
- 纠正期24小时内两eGFR亚组均有82%患者达到血钾正常,72小时内eGFR<30组为100%、≥30组为95%。
- 维持期第365天,eGFR<30组82%、≥30组90%维持血钾正常。
- 纠正期平均血清钾降低在维持期持续,血清碳酸氢盐升高。
- 维持期不良事件在eGFR<30亚组比≥30亚组更常见。
关键数值与推荐
- 基线eGFR<30 mL/min/1.73 m²者289例(39%),≥30者453例(60%),缺失9例(1%)。
- 纠正期SZC 10 g每日三次用24-72小时直至血钾正常(i-STAT钾3.5-5.0 mmol/L),维持期SZC 5 g每日一次用≤12个月。
临床怎么用
- 对CKD合并高钾血症门诊患者,可考虑使用SZC纠正并维持血钾正常,无需因CKD分期限制使用。
- eGFR<30 mL/min/1.73 m²患者维持期应更密切监测不良事件。
局限性
- 为开放标签、单臂研究的事后分析,缺乏对照组。
- 基线eGFR缺失9例(1%),可能影响分组准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safety >12 months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) versus those with Stages 1-3 CKD. METHODS: Adults with serum K+ ≥5.1 mmol/L (measured by point-of-care i-STAT device) received SZC 10 g three times daily for 24-72 h until normokalaemia (i-STAT K+ 3.5-5.0 mmol/L) was achieved [correction phase (CP)], followed by once daily SZC 5 g for ≤12 months [maintenance phase (MP)]. Here, patients were stratified by baseline estimated glomerular filtration rate (eGFR <30 or ≥30 mL/min/1.73 m2). Study endpoints included percent achieving normokalaemia during CP and MP, mean serum K+ and bicarbonate during MP, and adverse events (AEs). RESULTS: Of 751 patients enrolled, 289 (39%), 453 (60%) and 9 (1%) had baseline eGFR values of <30, ≥30 mL/min/1.73 m2 or missing, respectively. During the CP, 82% of patients achieved normokalaemia in both eGFR subgroups within 24 h, and 100 and 95% with baseline eGFR <30 and ≥30 mL/min/1.73 m2, respectively, within 72 h. Corresponding proportions with normokalaemia during the MP were 82 and 90% at Day 365, respectively. Mean serum K+ reduction from baseline during the CP was sustained throughout the MP and serum bicarbonate increased. AEs during the MP were more common in the eGFR <30 ≥30 mL/min/1.73 m2 subgroup. CONCLUSIONS: SZC corrects hyperkalaemia and maintains normokalaemia among outpatients regardless of the CKD stage.
引用
- Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant. 2021. PMID: 32030422. doi:10.1093/ndt/gfz285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。